BMS-690514 is primarily investigated for its potential in cancer therapy. It functions as an inhibitor targeting specific tyrosine kinases involved in cell signaling pathways that promote tumor growth and angiogenesis. By blocking these pathways, it aims to suppress the proliferation of cancer cells and inhibit the formation of new blood vessels that supply tumors. This makes it a promising candidate for treating various cancers, particularly those driven by abnormal kinase activity. Research is ongoing to evaluate its efficacy and safety in clinical trials, with a focus on its use in combination therapies or as a standalone treatment for advanced or resistant cancers.